NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of i
| Current Price | ₹939.30 |
|---|---|
| Market Cap | ₹16,824 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 11.9 |
| Return on Equity | 16.85% |
| 52-Week Range | ₹789.00 – ₹1,226.80 |
| Beta (1Y) | 0.19 |
| Dividend Yield | 0.48% |
1. Pharmaceuticals-96.6% 2. Agro Chemicals-3.4%
Natco Pharma Ltd is trading at ₹939.30, with a market capitalisation of ₹16,824 Cr.
Natco Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Natco Pharma Ltd has a P/E of 11.9 and a return on equity of 16.85%.